
Dermatology
Latest News
Latest Videos

CME Content
More News

The FDA has extended the approved use of Bryhali (halobetasol propionate) Lotion .01% for up to 8 weeks in adults with plaque psoriasis.

The FDA has accepted Sanofi’s supplemental biologics license application (sBLA) for priority review of dupilumab (Dupixent) in patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Patients treated with the RECELL Systems were required to donate 97.5% less skin than standard-of-care, and reported statistically significant reduction in patient-reported pain, increases in satisfaction, and improved outcomes in donor scars.

The patient population tends to have a more unbalanced immune profile to that of European American patients, indicating a potential for tailored treatment options to combat inflammation.

Novartis reported that 59% of patients at 24 weeks experienced little to no impact of their condition on their quality of life. Additionally, 87% of bio-naïve psoriasis patients remained on secukinumab through 12 months, indicating its tolerability in real-world settings.

The FDA has granted an orphan drug designation to Syntimmune Inc.’s SYNT001 for the treatment of pemphigus.

The FDA has granted a fast track designation to Immune Pharmaceuticals, Inc.’s bertilimumab for the treatment of bullous pemphigoid.

Altreno is a lotion containing .05% tretinoin, a retinoid that reduces inflammation and lesions associated with acne vulgaris.

Diacerein 1% ointment (CCP-020) received a fast track designation from the FDA for the treatment of epidermolysis bullosa simplex.

Krystal Biotech’s KB105 has received an orphan drug designation by the FDA for the treatment of patients with transglutaminase 1 deficient autosomal recessive congenital ichthyosis.

In a trio of phase 3 studies, omadacycline met the FDA-designated primary and secondary efficacy outcomes while reporting consistent safety measures and tolerability.

The first human clinical trial to assess RNA therapy, QR-313, for the treatment of recessive dystrophic epidermolysis bullosa has been initiated.

The virus was deemed eradicated by the World Health Organization in 1980. But there remains public concern of its use as a bioweapon.

The fixed-dose combination therapy from Valeant Pharmaceuticals International is vying to become the first and only approved topical lotion for the condition.

The rare condition affects 30,000-40,000 US patients annually. Rituximab becomes its first indicated biologic treatment.

CIMZIA is the first Fc-free biologic of its kind for this patient population.

Daniel de Boer, CEO of ProQR, Rare Disease Report ® discusses the company’s new RNA therapy, QR-313, for the treatment of dystrophic epidermolysis bullosa (DEB).

Taltz (ixekizumab) is the first FDA-approved treatment for moderate to severe plaque psoriasis that includes data on psoriasis in the genital area.

Fibrocell Science, Inc released interim results and progress regarding its phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

All told, 41.5% of those receiving dupilumab every 2 weeks and 38% of those receiving it every 4 weeks achieved an Eczema Area and Severity Index score ≥75%, compared with 8% of those receiving placebo.

The FDA granted rare pediatric disease designation to Castle Creek Pharmaceuticals (CCP) for diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS).

The safety and efficacy of diacerein 1% ointment is being evaluated in the DELIVERS study.

Positive results yield from a phase 2 tudy of bertilimumab in patients with moderate-to-extensive bullous pemphigoid (BP).

Actemra offers an alternative delivery option to physicians and parents of children 2 years or older to treat PJIA.

An injectable soluble formulation of naturally-secreted growth factors developed by Histogen will begin its first company-sponsored clinical trial.






















































